Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2012
12/05/2012EP2529743A1 Prophylactic or therapeutic agent for crohn's disease comprising organic acid polymer as active ingredient
12/05/2012EP2529742A1 Pharmaceutical composition comprising dapagliflozin and cyclodextrin
12/05/2012EP2529741A1 Composition and Tablet Comprising Raltegravir
12/05/2012EP2529740A1 Methods of preparing 4-Phenyl-6(2,2,2-Trifluoro-1-Phenylethoxy) Pyrimidine-based compounds.
12/05/2012EP2529739A1 Therapeutic or prophylactic agent for biliary diseases
12/05/2012EP2529738A1 Substituted terpyridines
12/05/2012EP2529737A1 Antibacterial combination therapy
12/05/2012EP2529736A1 Expression promoter for redox-related factor
12/05/2012EP2529735A1 Novel 4-(heterocycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof in human medicine and also in cosmetics
12/05/2012EP2529734A1 Nitrate esters and their use for the treatment of muscle and muscle related diseases
12/05/2012EP2529733A1 Antibacterial combination therapy
12/05/2012EP2529731A1 Particulate preparation and method for producing the same
12/05/2012EP2529729A1 Balsalazide formulations and manufacture thereof
12/05/2012EP2529728A1 Pharmaceutical compositions for the treatment of bacterial infections
12/05/2012EP2529622A1 Inhibitors of bruton's tyrosine kinase
12/05/2012EP2529621A1 Inhibitors of bruton's tyrosine kinase
12/05/2012EP2529620A1 Composition for control of animal parasites, and method for control of animal parasites
12/05/2012EP2529015A2 Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
12/05/2012EP2529005A1 Use of hydrogels on the basis of guluronic acid- and/or mannuronic acid-containing polysaccharides for treating damage to the nervous system, promoting nerve growth, treating neurodegenerative diseases and cultivating neurons
12/05/2012EP2528930A1 4 ' - azido - nucleosides as anti - hcv compunds
12/05/2012EP2528926A1 Hepatitis c inhibitor compounds
12/05/2012EP2528922A1 Polyheterocyclic compounds highly potent as hcv inhibitors
12/05/2012EP2528921A2 7-azoniabicyclo [2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
12/05/2012EP2528920A2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
12/05/2012EP2528919A1 Compositions and methods for treating toxoplasmosis. cryptosporidiosis and other apicomplexan protozoan related diseases
12/05/2012EP2528918A1 6,7- dihydroimidazo [1,5-a]pyrazin-8 (5h) - one derivatives as protein kinase modulators
12/05/2012EP2528917A1 Pyrazolopyridine kinase inhibitors
12/05/2012EP2528916A1 Pyrazolopyridine kinase inhibitors
12/05/2012EP2528915A1 Substituted naphthyridines and their use as syk kinase inhibitors
12/05/2012EP2528911A2 Compositions and methods for enhancing proteasome activity
12/05/2012EP2528910A1 5-alkynyl pyrimidines and their use as kinase inhibitors
12/05/2012EP2528909A1 Sulfonamido derivatives of 3,4-diarylpyrazoles as protein kinase inhibitors
12/05/2012EP2528908A1 Therapeutic agents for treatment of ocular hypertension
12/05/2012EP2528907A1 Therapeutically active cyclopentanes
12/05/2012EP2528904A1 Production and use of antibacterial, antiproliferative, and antiphytopathogenic benzanthracenes
12/05/2012EP2528903A1 5-alkynyl-pyrimidines
12/05/2012EP2528902A1 Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals
12/05/2012EP2528901A1 Pyrazole compounds as crth2 antagonists
12/05/2012EP2528898A2 NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD)
12/05/2012EP2528897A1 Di - substituted pyridine derivatives as anticancers
12/05/2012EP2528895A2 Trypsin-like serine protease inhibitors, and their preparation and use
12/05/2012EP2528894A1 Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
12/05/2012EP2528893A2 Small molecules for the modulation of mcl-1 and methods of modulatiing cell death, cell division, cell differentiation and methods of treating disorders
12/05/2012EP2528659A1 Methods for regulating blood glucose levels
12/05/2012EP2528613A1 Method for treating liver disorders with receptor associated protein ( irp) peptide-fucosidase inhibitor conjugates
12/05/2012EP2528607A2 Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
12/05/2012EP2528606A1 Quinazoline-based t cell proliferation inhibitors
12/05/2012EP2528605A1 Therapies for treating hepatitis c virus infection
12/05/2012EP2528604A2 Acyl piperidine inhibitors of soluble epoxide hydrolase
12/05/2012EP2528603A1 Pharmaceutical compositions for the treatment of pain and other indicatons
12/05/2012EP2528602A1 Formulations of bendamustine
12/05/2012EP2528601A1 Compositions and methods for prevention and treatment of pulmonary hypertension
12/05/2012EP2528600A1 Dry powder pharmaceutical composition comprising tiotropium and fluticasone
12/05/2012EP2528599A1 Novel polymorph of the hydrochloride of the (4-hydroxycarbamoyl-phenyl)-carbamic acid (6-dimethylamino methyl-2-naphtalenyl) ester
12/05/2012EP2528598A1 Compounds for suppressing a peripheral nerve disorder induced by an anti - cancer agent
12/05/2012EP2528597A1 Dry powder formulation comprising a pharmaceutical combination of tiotropium bromide, formoterol fumarate and mometasone furoate
12/05/2012EP2528596A1 Dry powder formulations administered by the inhalation route comprising a combination of tiotropium bromide, salmeterol xynafoate and fluticasone propionate.
12/05/2012EP2528595A1 Compounds for use in the treatment of diseases
12/05/2012EP2528594A2 Effervescent formulations comprising second generation cephalosporin
12/05/2012EP2528593A2 Effervescent formulations comprising cefprozil as active agent
12/05/2012EP2528591A2 Effervescent formulations comprising cefaclor
12/05/2012EP2528589A2 Stable efervescent formulations comprising cefaclor
12/05/2012EP2528587A1 Methods for internally controlling or treating equine bot larvae
12/05/2012EP2528586A1 Effervescent formulations comprising cefixime and clavulanic acid as active agents
12/05/2012EP2528585A1 Pharmaceutical compositions comprising tiotropium, formoterol and budesonide
12/05/2012EP2528584A1 Water dispersible cefdinir and clavulanic acid formulations for treatment of bacterial infections
12/05/2012EP2528459A1 Nutritional emulsions comprising calcium hmb
12/05/2012EP2528444A2 Topical antiparasitic formulations
12/05/2012EP2528443A1 Quantitative analysis of vitamin d3, vitamin d2, and metabolites thereof
12/05/2012EP2528441A1 Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
12/05/2012EP2528440A1 Substituted norindenoisoquinolines, syntheses thereof, and methods of use
12/05/2012EP2528438A1 Ph responsive fluorescent false neurotransmitters and their use
12/05/2012EP2528437A1 Methods for treating or preventing the spread of cancer using semi-synthetic glycosaminoglycosan ethers
12/05/2012EP2079456B1 Pharmaceutical cyclosporin compositions
12/05/2012DE202012000250U1 Zusammensetzung für die topische Anwendung I A composition for topical application I
12/05/2012CN202568934U Tablet capsule filled with glipizide solid preparations and metformin solid preparations
12/05/2012CN202568933U Novel amlodipine and benazepril capsule
12/05/2012CN202568932U Novel capsule containing irbesartan solid preparation and hydrochlorothiazide solid preparation
12/05/2012CN202568931U Novel compound capsule containing ferrous fumarate and folic acid
12/05/2012CN202568930U Tablet capsule with repaglinide solid preparation and dimethyldiguanide solid preparation
12/05/2012CN202568929U Tablet capsules containing rosiglitazone solid preparation and metformin solid preparation
12/05/2012CN202568928U Tablet capsule filled with valsartan tablet and amlodipine tablet
12/05/2012CN202568927U Novel capsule containing Roflumilast solid preparation and Formoterol solid preparation
12/05/2012CN202568926U Tablet capsule filled with alogliptin solid preparation and pioglitazone solid preparation
12/05/2012CN202568925U Tablet capsule filled with valsartan solid preparation and hydrochlorothiazide solid preparation
12/05/2012CN202568924U Tablet capsule with losartan tablet and hydrochlorothiazide tablet
12/05/2012CN202568893U System for preparing multi-vitamin
12/05/2012CN1981749B Use of beta-elemene for inhibiting cerebrovascular endothelial cell
12/05/2012CN1976704B Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
12/05/2012CN1893977B Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient.
12/05/2012CN102812049A 抗过敏剂 Antiallergic agent
12/05/2012CN102812048A Allergy inhibitor
12/05/2012CN102812029A Pyrrolopyrazine derivatives and their use as JAK and SYK inhibitors
12/05/2012CN102812028A Tricyclic indazole compound, method of preparation and pharmaceutical composition containing it
12/05/2012CN102812027A Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
12/05/2012CN102812023A Anti - infective pyrido (1,2 -a) pyrimidines
12/05/2012CN102812022A Thiazole and oxazole kinase inhibitors
12/05/2012CN102812021A Unsaturated Fatty Acid Monoesters And Diesters On Ascorbic Acid And Cosmetic Uses Thereof
12/05/2012CN102812017A Pyrazine derivatives
12/05/2012CN102812015A Antiprotozoal compound originating in coelenterata
1 ... 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 ... 7860